Adma Biologics (ADMA) Tax Provisions (2011 - 2025)
Adma Biologics (ADMA) reported Tax Provisions of $12.2 million for Q4 2025, up 115.83% on a YoY basis from $5.7 million in Q4 2024, and up 10.18% quarter-over-quarter from $11.1 million in Q3 2025.
Adma Biologics (ADMA) Tax Provisions (2011 - 2025) Analysis & Trends
Adma Biologics has reported Tax Provisions for 4 years, with the latest figure at $12.2 million in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions rose 115.83% year-over-year to $12.2 million; the trailing twelve-month figure through Dec 2025 stood at $35.7 million (up 149.65% YoY), and the FY2025 full-year result was $35.7 million, up 149.65% from the prior year.
- Tax Provisions for Q4 2025 stood at $12.2 million, up from $11.1 million in the prior quarter.
- The five-year high for Tax Provisions was $12.2 million in Q4 2025, with the low at -$77.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn | 12.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.22 Mn |
| Sep 30, 2025 | 11.09 Mn |
| Jun 30, 2025 | 5.88 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | -77.18 Mn |
| Sep 30, 2024 | 840,000.00 |
| Jun 30, 2024 | 3.79 Mn |
| Mar 31, 2024 | 595,000.00 |
| Mar 31, 2012 | -617,615.00 |
| Mar 31, 2011 | -320,765.00 |